Thrivent Financial For Lutherans Deciphera Pharmaceuticals, Inc. Transaction History

Thrivent Financial For Lutherans

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$13.58 - $17.36 $110,609 - $141,397	-8,145 Reduced 10.48%	69,575 $1.09 Million
Q4 2023 Feb 14, 2024	SELL	$10.11 - $16.54 $90,292 - $147,718	-8,931 Reduced 10.31%	77,720 $1.25 Million
Q3 2023 Nov 14, 2023	SELL	$12.46 - $15.48 $662,348 - $822,885	-53,158 Reduced 38.02%	86,651 $1.1 Million
Q2 2023 Aug 14, 2023	SELL	$13.28 - $15.96 $91,220 - $109,629	-6,869 Reduced 4.68%	139,809 $1.97 Million
Q4 2022 Feb 08, 2023	SELL	$14.85 - $19.04 $767,121 - $983,568	-51,658 Reduced 26.05%	146,678 $2.4 Million
Q3 2022 Nov 14, 2022	BUY	$12.38 - $20.23 $2.46 Million - $4.01 Million	198,336 New	198,336 $3.67 Million
Q1 2021 May 17, 2021	SELL	$40.39 - $56.73 $536,379 - $753,374	-13,280 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$51.77 - $66.18 $195,587 - $250,028	3,778 Added 39.76%	13,280 $758,000
Q3 2020 Nov 10, 2020	SELL	$43.8 - $58.16 $170,338 - $226,184	-3,889 Reduced 29.04%	9,502 $487,000
Q2 2020 Aug 12, 2020	BUY	$37.05 - $65.03 $139,974 - $245,683	3,778 Added 39.3%	13,391 $800,000
Q1 2020 May 15, 2020	BUY	$33.63 - $69.4 $323,285 - $667,142	9,613 New	9,613 $396,000

293K

500

Ticker DCPH
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 66,822,100
Description
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...

Get notified when there are updates to the investment portfolio of Thrivent Financial For Lutherans, based on Form 13F filings with the SEC.

Stay updated on Thrivent Financial For Lutherans with notifications on news.